Forte Biosciences (FBRX) Free Cash Flow Growth (1y) (2017 - 2026)
Forte Biosciences (FBRX) Free Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 137.65% |
| 10 | Forte Biosciences | 1.36 Bn | 1.31 Bn | - | -80.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.49% |
| Dec 31, 2025 | -64.18% |
| Sep 30, 2025 | -72.81% |
| Jun 30, 2025 | -69.49% |
| Mar 31, 2025 | -56.09% |
| Dec 31, 2024 | -11.73% |
| Sep 30, 2024 | 10.62% |
| Jun 30, 2024 | -8.42% |
| Mar 31, 2024 | -28.23% |
| Dec 31, 2023 | -210.61% |
| Sep 30, 2023 | -369.02% |
| Jun 30, 2023 | -297.60% |
| Mar 31, 2023 | -163.49% |
| Dec 31, 2022 | 19.24% |
| Sep 30, 2022 | 62.16% |
| Jun 30, 2022 | 65.03% |
| Mar 31, 2022 | 50.99% |
| Dec 31, 2021 | 5.81% |
| Sep 30, 2021 | 33.75% |
| Jun 30, 2021 | 1.94% |